We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis.
- Authors
Okawada, Manabu; Koga, Hiroyuki; Larsen, Scott; Showalter, Hollis; Turbiak, Anjanette; Jin, Xiaohong; Lucas, Peter; Lipka, Elke; Hillfinger, John; Kim, Jae; Teitelbaum, Daniel; Larsen, Scott D; Showalter, Hollis D; Turbiak, Anjanette J; Lucas, Peter C; Kim, Jae Seung; Teitelbaum, Daniel H
- Abstract
<bold>Background: </bold>Renin-angiotensin system blockade reduces inflammation in several organ systems. Having found a fourfold increase in angiotensin II type Ia receptor expression in a dextran sodium sulfate colitis model, we targeted blockade with angiotensin II type Ia receptor antagonists to prevent colitis development. Because hypotension is a major complication of angiotensin II type Ia receptor antagonists use, we hypothesized that use of angiotensin II type Ia receptor antagonists compounds which lack cell membrane permeability, and thus enteric absorption, would allow for direct enteral delivery at far higher concentrations than would be tolerated systemically, yet retain efficacy.<bold>Methods: </bold>Based on the structure of the angiotensin II type Ia receptor antagonist losartan, deschloro-losartan was synthesized, which has extremely poor cell membrane permeability. Angiotensin II type Ia receptor antagonist efficacy was evaluated by determining the ability to block NF-κB activation in vitro. Dextran sodium sulfate colitis was induced in mice and angiotensin II type Ia receptor antagonist efficacy delivered transanally was assessed.<bold>Results: </bold>In vitro, deschloro-losartan demonstrated near equal angiotensin II type Ia receptor blockade compared to losartan as well as another angiotensin II type Ia receptor antagonist, candesartan. In the dextran sodium sulfate model, each compound significantly improved clinical and histologic scores and epithelial cell apoptosis. Abundance of TNF-α, IL-1β, and IL6 mRNA were significantly decreased with each compound. In vitro and in vivo intestinal drug absorption, as well as measures of blood pressure and mucosal and colonic blood flow, showed significantly lower uptake of deschloro-losartan compared to losartan and candesartan.<bold>Conclusions: </bold>This study demonstrated efficacy of high-dose angiotensin II type Ia receptor antagonists in this colitis model. We postulate that a specially designed angiotensin II type Ia receptor antagonist with poor oral absorption may have great potential as a new therapeutic agent for inflammatory bowel disease in the future.
- Subjects
ANGIOTENSIN II; COLITIS; INFLAMMATION; CELL membranes; LOSARTAN; SODIUM sulfate; BLOOD flow; DEXTRAN; NF-kappa B; ANIMAL experimentation; COLON (Anatomy); COMPARATIVE studies; CYTOKINES; FECES; GENES; HETEROCYCLIC compounds; RESEARCH methodology; MEDICAL cooperation; MICE; MOLECULAR structure; ORAL drug administration; RESEARCH; RESEARCH funding; EVALUATION research; ANGIOTENSIN receptors; PHARMACODYNAMICS
- Publication
Digestive Diseases & Sciences, 2011, Vol 56, Issue 9, p2553
- ISSN
0163-2116
- Publication type
journal article
- DOI
10.1007/s10620-011-1651-9